Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | KDM6B | O15054 | 2/20 | 0.71 |
| ▸ | KDM5C | P41229 | 2/20 | 0.71 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.71 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.71 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.71 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.60 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772302 | 0.97 | KDM4E (0.68) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL3718393 | 0.97 | KDM4E (0.68) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL15173414 | 0.90 | KDM4E (0.67) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL28509907 | 0.89 | KDM4E (0.61) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL27997808 | 0.89 | KDM4E (0.69) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL3709493 | 0.87 | KDM4E (0.59) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1579012 | 0.87 | KDM4E (0.67) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL3713394 | 0.86 | ABL1 (0.66) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30151105 | 0.86 | ABL1 (0.66) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL29894587 | 0.86 | KDM4E (0.86) | KDM4EKDM6BKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118745147-A | Cobalt-catalyzed method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-10-08 | — | — | CN | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117430549-A | Method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
| CN-112048734-B | Regioselective electrochemical synthesis method of nitrogen-containing aromatic heterocyclic carboxylic ester | 四川大学 | 2022-06-10 | — | — | CN | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | KDM4E 4675/4885KDM6B 4757/4885KDM5C 4673/4885 |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | KDM4E 710/4885KDM6B 516/4885KDM5C 751/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | KDM4E 4661/4885KDM6B 4148/4885KDM5C 4397/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | KDM4E 4675/4885KDM6B 4757/4885KDM5C 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.